Store

Clinical Trials

Why Clinical Trials?

Angiosarcoma Clinical Trials

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
More Information
Status
Recruiting

Regorafenib in Treating Patients with Previously Treated, Metastatic, or Locally Advanced Angiosarcoma

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Refractory, Metastatic and Locally Advanced Angiosarcoma
This phase II trial studies regorafenib in treating patients with previously treated angiosarcoma that has spread to other places in the body (metastatic) or spread from where it started to nearby tissue or lymph nodes (locally advanced). Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
More Information
Status
Recruiting

Sarcoma Clinical Trials

Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Phase III
The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.

The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin

plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with

advanced or metastatic soft tissue sarcoma.

More Information
Status
Recruiting

Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
This phase II trial studies how well cediranib maleate works in treating patients with soft tissue sarcoma that has spread to other places in the body. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by preventing the growth of new blood vessels that […]
This phase II trial studies how well cediranib maleate works in treating patients with soft tissue sarcoma that has spread to other places in the body. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by preventing the growth of new blood vessels that tumors need to grow.
More Information
Status
Recruiting

Alisertib in Treating Patients with Advanced or Metastatic Sarcoma

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
This phase II trial studies how well alisertib works in treating patients with advanced or metastatic sarcoma. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This phase II trial studies how well alisertib works in treating patients with advanced or metastatic sarcoma. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
More Information
Status
Recruiting

Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic

Phase I
Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat with combination chemotherapy […]
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat with combination chemotherapy may kill more tumor cells.
More Information
Status
Recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
This randomized phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with sarcoma that has spread from the primary site to other parts of the body or cannot be removed by surgery. Monoclonal antibodies, such as nivolumab and ipilimumab, may block tumor growth in different ways by targeting certain […]
This randomized phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with sarcoma that has spread from the primary site to other parts of the body or cannot be removed by surgery. Monoclonal antibodies, such as nivolumab and ipilimumab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether nivolumab works better with or without ipilimumab in treating patients with metastatic or unresectable sarcoma.
More Information
Status
Pending
Collaborators
National Cancer Institute (NCI)

TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

Phase IB
A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
More Information
Status
Recruiting

Solid Metastatic Tumor Clinical Trials

Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic

Phase I
Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat with combination chemotherapy […]
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat with combination chemotherapy may kill more tumor cells.
More Information
Status
Recruiting

All content of this Site, such as text, graphics, images, comments, information, and other material contained on this site are for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on Angiosarcoma’s website or affiliated social media accounts.

If you think you may have a medical emergency, call your doctor or 911 immediately. Angiosarcoma Awareness does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the site. Reliance on any information provided by Angiosarcoma Awareness, Inc., Angiosarcoma Awareness members, or others appearing on the site at the invitation of Angiosarcoma Awareness, or other visitors to the Site is solely at your own risk.